✨ Free AI Report
Eli Lilly and Company: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Eli Lilly and Company
Company Research

Eli Lilly and Company: Business Overview, Financials & Competitive Analysis

Eli Lilly is a medicine company turning science into healing to make life better for people around the world, having pioneered life-changing discoveries for nearly 150 years and today helping tens of millions of peopl...

Analyst-debate audio for Eli Lilly and Company

AskCyborg analysts argue the bull and bear cases for Eli Lilly and Company across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
9/ 10Exceptional

Cyborg Score thesis

Lilly is a best-in-class pharmaceutical leader riding exceptional cardiometabolic demand with differentiated pipeline and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Eli Lilly and Company Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Eli Lilly and Company Overview

Pro stress-test →

Eli Lilly is a medicine company turning science into healing to make life better for people around the world, having pioneered life-changing discoveries for nearly 150 years and today helping tens of millions of people across the globe. In Q1 2026, worldwide revenue reached $19.8 billion, an increase of 56% compared with Q1 2025, driven by a 65% increase in volume, particularly powered by its blockbuster GLP-1 drugs Mounjaro and Zepbound.

Strategic Profile

Pro stress-test →

Lilly commands 60.1% market share of the U.S. obesity and diabetes drug market in Q1 2026, with competitor Novo Nordisk holding 39.4%. The company has generated significant momentum through aggressive dealmaking activity in 2026, completing six M&A deals and spending around $21 billion in total, including the $2.3 billion acquisition of blood cancer specialist Ajax Therapeutics.

Competitive Landscape

Pro stress-test →

Lilly maintains commanding 60.1% market share in the U.S. obesity and diabetes drug market, with Novo Nordisk as primary competitor at 39.4% market share. The company competes in immunology, oncology, and neuroscience segments with diversified portfolio and strong late-stage pipeline across multiple therapeutic areas, positioning it to sustain competitive advantages beyond the current GLP-1 cycle.

Industry Context

Eli Lilly and Company operates in Pharmaceuticals.

Key facts

Founded: 1876 · Headquarters: Indianapolis, Indiana, US · Employees: 40000+ · Revenue: $82-85B (2026 guidance) · Market cap: $1.9T

What the analysts stress-tested

The top findings that survived the multi-agent debate for Eli Lilly and Company.

  • FDA approval of Foundayo—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions—will meaningfully expand the number of people who can benefit from GLP-1s.
  • Global GLP-1 use is expected to rise from approximately 20 million patients at end of 2025 to 30 million at end of 2026, representing significant runway for continued growth.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Raised full-year 2026 revenue guidance by $2 billion to $82-$85 billion range following strong Q1 results with 56% revenue growth
  • April 2026FDA approved Foundayo (orforglipron), first oral GLP-1 pill for weight loss with convenient dosing; early market reception positive across payers and telehealth platforms
  • +1 moreTrack every material event for Eli Lilly and Company as it happens. Explore monitoring →
Get alerted when Eli Lilly and Company has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ozempic/WegovyGLP-1 obesity and diabetes treatments competing in cardiometabolic space→Various oncology productsOncology and immunology competition across multiple indications→Various pharmaceutical productsBroad portfolio competitor across multiple therapeutic areas→Various pharmaceutical productsGlobal pharmaceutical and diagnostics competitor→

Compare Eli Lilly and Company with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Eli Lilly and Company operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Eli Lilly and Company

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Eli Lilly and Company and its top competitor on Cyborg Score”
“What did Eli Lilly and Company do this quarter?”
“Is Eli Lilly and Company a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Eli Lilly and Company do?+
Eli Lilly is a medicine company turning science into healing to make life better for people around the world, having pioneered life-changing discoveries for nearly 150 years and today helping tens of millions of peopl...
What is Eli Lilly and Company's Cyborg Score?+
Eli Lilly and Company has a Cyborg Score of 9/10 (Exceptional). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Eli Lilly and Company's main competitors?+
Named competitors include Ozempic/Wegovy, Various oncology products, Various pharmaceutical products, Various pharmaceutical products. The full competitive landscape is in the AskCyborg report.
How can I get the full Eli Lilly and Company research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Eli Lilly and Company research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Eli Lilly and Company over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.